PRESS RELEASES

Date	Title
Oct 10, 2019	Ardelyx to Host Analyst Day in New York
Sep 17, 2019	Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 12, 2019	Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
Sep 3, 2019	Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Sep 2, 2019	Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Aug 9, 2019	Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
May 30, 2019	Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
May 7, 2019	Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Mar 14, 2019	Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Mar 7, 2019	Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com